Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health–AARP Diet and Health Study
Open Access
- 30 April 2008
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 10 (2), R38
- https://doi.org/10.1186/bcr2089
Abstract
By inhibiting cyclooxygenase-2, nonsteroidal anti-inflammatory drugs (NSAIDs) decrease aromatase activity and might reduce breast cancer risk by suppressing estrogen synthesis. Epidemiologic evidence for a protective role of NSAIDs in breast cancer, however, is equivocal.Keywords
This publication has 48 references indexed in Scilit:
- Aspirin use and breast cancer risk: a meta‐analysis and meta‐regression of observational studies from 2001 to 2005Pharmacoepidemiology and Drug Safety, 2008
- Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancerBreast Cancer Research, 2007
- The role of cyclooxygenase-2 in breast cancer: reviewBreast Cancer Research and Treatment, 2007
- A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer IncidenceJNCI Journal of the National Cancer Institute, 2007
- Cigarettes: A Smoking Gun in Cancer ChemopreventionJNCI Journal of the National Cancer Institute, 2005
- Low-Dose Aspirin in the Primary Prevention of CancerJAMA, 2005
- Design and Serendipity in Establishing a Large Cohort with Wide Dietary Intake DistributionsAmerican Journal of Epidemiology, 2001
- Breast cancer and NSAID use: a meta-analysisBritish Journal of Cancer, 2001
- The Relationship of Nonsteroidal Anti-inflammatory Drug Use to the Risk of Breast CancerPreventive Medicine, 1999
- Breast Cancer and NSAID Use: Heterogeneity of Effect in a Case-Control StudyPreventive Medicine, 1995